PDCD1 and neoplasm: Therefore, blocking PD-1/PD-L1 signaling can activate APCs [67,73,74,75] and ICIs have a potential risk of shifting the immune balance from tumor-directed monocyte/macrophage activation to non-tumor-directed monocyte/macrophage activation through T cell activation, resulting in common and unexpected irAEs, such as disorders of coagulation-fibrinolysis system [13,14,15] (Figure 5, Figure 6 and Figure 7).